{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:42:07Z","timestamp":1792006927475,"version":"4.4.0"},"reference-count":36,"publisher":"American Diabetes Association","issue":"4","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016545","name":"Roche Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Previous genetic and clinical analyses have associated lower lipoprotein(a) and LDL cholesterol (LDL-C) with greater risk of new-onset type 2 diabetes (NOD). However, PCSK9 inhibitors such as alirocumab lower both lipoprotein(a) and LDL-C without effect on NOD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>In a post hoc analysis of the ODYSSEY OUTCOMES trial (NCT01663402), we examined the joint prediction of NOD by baseline lipoprotein(a), LDL-C, and insulin (or HOMA\u2013insulin resistance [HOMA-IR]) and their changes with alirocumab treatment. Analyses included 8,107 patients with recent acute coronary syndrome on optimized statin therapy, without diabetes at baseline, assigned to alirocumab or placebo with median follow-up 2.4 years. Splines were estimated from logistic regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Lower baseline lipoprotein(a) and higher baseline insulin or HOMA-IR independently predicted 782 cases of NOD; baseline LDL-C did not predict NOD. Alirocumab reduced lipoprotein(a) and LDL-C without affecting insulin or NOD risk (odds ratio [OR] vs. placebo 0.998; 95% CI 0.860\u20131.158). However, in logistic regression, decreased lipoprotein(a) and LDL-C on alirocumab were independent, opposite predictors of NOD. OR for NOD for 25% and 50% lipoprotein(a) reductions on alirocumab were 1.12 (95% CI 1.01\u20131.23) and 1.24 (1.02\u20131.52). OR for NOD for 25% and 50% LDL-C reductions on alirocumab were 0.88 (95% CI 0.80\u20130.97) and 0.77 (0.64\u20130.94).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Baseline lipoprotein(a) was inversely associated with risk of NOD. Alirocumab-induced reductions of lipoprotein(a) and LDL-C were associated with increased and decreased risk of NOD, respectively, without net effect on NOD. Ongoing trials will determine the impact of larger and longer lipoprotein(a) reductions on NOD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc24-2110","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T14:05:51Z","timestamp":1738850751000},"page":"596-604","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":13,"title":["Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial"],"prefix":"10.2337","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2954-0695","authenticated-orcid":false,"given":"Gregory G.","family":"Schwartz","sequence":"first","affiliation":[{"name":"1Division of Cardiology, University of Colorado School of Medicine, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Szarek","sequence":"additional","affiliation":[{"name":"1Division of Cardiology, University of Colorado School of Medicine, Aurora, CO"},{"name":"2CPC Clinical Research, Aurora, CO"},{"name":"3State University of New York Downstate Health Sciences University, Brooklyn, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Wouter","family":"Jukema","sequence":"additional","affiliation":[{"name":"4Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands"},{"name":"5Netherlands Heart Institute, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa M.","family":"Cobbaert","sequence":"additional","affiliation":[{"name":"6Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Reijnders","sequence":"additional","affiliation":[{"name":"6Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera A.","family":"Bittner","sequence":"additional","affiliation":[{"name":"7Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schwertfeger","sequence":"additional","affiliation":[{"name":"8Roche Diagnostics International, Zug, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"9Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Fazio","sequence":"additional","affiliation":[{"name":"10Regeneron Pharmaceuticals, Tarrytown, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Garon","sequence":"additional","affiliation":[{"name":"11Sanofi, North York, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun G.","family":"Goodman","sequence":"additional","affiliation":[{"name":"12Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada"},{"name":"13St. Michael\u2019s Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Harrington","sequence":"additional","affiliation":[{"name":"14Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey D.","family":"White","sequence":"additional","affiliation":[{"name":"15Green Lane Cardiovascular Research Unit, Te Whatu Ora\u2013Health New Zealand and University of Auckland, Te Toka Tumai, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"16Universit\u00e9 Paris-Cit\u00e9, INSERM-UMR1148, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bichat, French Alliance for Cardiovascular Trials, Institut Universitaire de France, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"2025032118523228700_B1","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2025032118523228700_B2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/00325481.2017.1342508","article-title":"Lipoprotein(a)-activated immunity, insulin resistance and new-onset diabetes","volume":"129","author":"Kaya","year":"2017","journal-title":"Postgrad Med"},{"key":"2025032118523228700_B3","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"2025032118523228700_B4","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/eurheartj\/ehaa1085","article-title":"Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study","volume":"42","author":"Langsted","year":"2021","journal-title":"Eur Heart J"},{"key":"2025032118523228700_B5","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1373\/clinchem.2010.146779","article-title":"Lipoprotein(a) and risk of type 2 diabetes","volume":"56","author":"Mora","year":"2010","journal-title":"Clin Chem"},{"key":"2025032118523228700_B6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12933-017-0520-z","article-title":"Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature","volume":"16","author":"Paige","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"2025032118523228700_B7","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2337\/db13-1144","article-title":"The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?","volume":"63","author":"Ye","year":"2014","journal-title":"Diabetes"},{"key":"2025032118523228700_B8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12944-017-0564-9","article-title":"The mixed benefit of low lipoprotein(a) in type 2 diabetes","volume":"16","author":"Hermans","year":"2017","journal-title":"Lipids Health Dis"},{"key":"2025032118523228700_B9","doi-asserted-by":"crossref","first-page":"e0177500","DOI":"10.1371\/journal.pone.0177500","article-title":"Insulin resistance contributes more to the increased risk for diabetes development in subjects with low lipoprotein(a) level than insulin secretion","volume":"12","author":"Rhee","year":"2017","journal-title":"PLoS One"},{"key":"2025032118523228700_B10","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.33549\/physiolres.933583","article-title":"Inverse association of lipoprotein (a) with markers of insulin resistance in dyslipidemic subjects","volume":"66","author":"Vaverkov\u00e1","year":"2017","journal-title":"Physiol Res"},{"key":"2025032118523228700_B11","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1475-2840-12-138","article-title":"Lipoprotein(a) is not related to markers of insulin resistance in pregnancy","volume":"12","author":"Todoric","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"2025032118523228700_B12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12933-022-01714-2","article-title":"Investigating sex-specific associations of lipid traits with type 2 diabetes, glycemic traits and sex hormones using Mendelian randomization","volume":"22","author":"Yang","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"2025032118523228700_B13","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N Engl J Med"},{"key":"2025032118523228700_B14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrendo.2015.194","article-title":"The diabetogenic action of statins - mechanisms and clinical implications","volume":"12","author":"Betteridge","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"2025032118523228700_B15","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","article-title":"Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial","volume":"7","author":"Ray","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025032118523228700_B16","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025032118523228700_B17","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1111\/dom.15650","article-title":"Inclisiran in individuals with diabetes or obesity: post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 phase 3 randomized trials","volume":"26","author":"Leiter","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2025032118523228700_B18","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2337\/dc20-2842","article-title":"Relation of lipoprotein(a) levels to incident type 2 diabetes and modification by alirocumab treatment","volume":"44","author":"Schwartz","year":"2021","journal-title":"Diabetes Care"},{"key":"2025032118523228700_B19","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2025032118523228700_B20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1161\/CIRCULATIONAHA.123.066398","article-title":"Relating lipoprotein(a) concentrations to cardiovascular event risk after acute coronary syndrome: a comparison of 3 tests","volume":"149","author":"Szarek","year":"2024","journal-title":"Circulation"},{"key":"2025032118523228700_B21","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"2025032118523228700_B22","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.120.049447","article-title":"Clinical efficacy and safety of alirocumab after acute coronary syndrome according to achieved level of low-density lipoprotein cholesterol: a propensity score-matched analysis of the ODYSSEY OUTCOMES trial","volume":"143","author":"Schwartz","year":"2021","journal-title":"Circulation"},{"key":"2025032118523228700_B23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11883-024-01187-6","article-title":"Lipoprotein(a): from causality to treatment","volume":"26","author":"Kronenberg","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"2025032118523228700_B24","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.2016.14568","article-title":"Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis","volume":"316","author":"Lotta","year":"2016","journal-title":"JAMA"},{"key":"2025032118523228700_B25","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jama.2015.1206","article-title":"Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus","volume":"313","author":"Besseling","year":"2015","journal-title":"JAMA"},{"key":"2025032118523228700_B26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","article-title":"Inflammation in obesity, diabetes, and related disorders","volume":"55","author":"Rohm","year":"2022","journal-title":"Immunity"},{"key":"2025032118523228700_B27","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/cvr\/cvz313","article-title":"PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1","volume":"116","author":"Ding","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2025032118523228700_B28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","article-title":"PCSK9 and inflammation: a review of experimental and clinical evidence","volume":"5","author":"Momtazi-Borojeni","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025032118523228700_B29","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jacc.2022.10.030","article-title":"PCSK9 inhibition during the inflammatory stage of SARS-CoV-2 infection","volume":"81","author":"Navarese","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025032118523228700_B30","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.2337\/diacare.20.8.1242","article-title":"Serum insulin and lipoprotein(a) concentrations. The Jichi Medical School Cohort Study","volume":"20","author":"Inoue","year":"1997","journal-title":"Diabetes Care"},{"key":"2025032118523228700_B31","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1194\/jlr.P082792","article-title":"LPA kringle IV type 2 is associated with type 2 diabetes in a Chinese population with very high cardiovascular risk","volume":"59","author":"Mu-Han-Ha-Li","year":"2018","journal-title":"J Lipid Res"},{"key":"2025032118523228700_B32","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1373\/clinchem.2017.277103","article-title":"Kringle IV type 2, not low lipoprotein(a), as a cause of diabetes: a novel genetic approach using SNPs associated selectively with lipoprotein(a) concentrations or with Kringle IV type 2 repeats","volume":"63","author":"Tolbus","year":"2017","journal-title":"Clin Chem"},{"key":"2025032118523228700_B33","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.31083\/j.rcm2204162","article-title":"Relationship between lipoprotein(a) and cardiovascular risk factors-data from 4602 participants of the ELITE study","volume":"22","author":"Schrader","year":"2021","journal-title":"Rev Cardiovasc Med"},{"key":"2025032118523228700_B34","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"2025032118523228700_B35","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10557-014-6534-9","article-title":"Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications","volume":"28","author":"Zafrir","year":"2014","journal-title":"Cardiovasc Drugs Ther"},{"key":"2025032118523228700_B36","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/ehjcvp\/pvac025","article-title":"The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis","volume":"8","author":"Dangas","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/4\/596\/797675\/dc242110.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/4\/596\/797675\/dc242110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T15:40:04Z","timestamp":1742571604000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/48\/4\/596\/157831\/Risk-of-Incident-Diabetes-Related-to-Lipoprotein-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2,6]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc24-2110","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}